AACE Guidelines

Reference Section
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients Update
a report by
The American Association of Clinical Endocrinologists H y p o g o n a d i s m Ta s k Fo rc e
Chairman Steven M Petak, MD, JD, FACE Committee Members Howard R Nankin, MD, FACE Richard F Spark, MD, FACE Ronald S Swerdloff, MD Luis J Rodriguez-Rigau, MD, FACE Reviewers Robert J Anderson, MD, FACE, FACP Donald A Bergman, MD, FACE Jeffrey R Garber, MD, FACE Carlos R Hamilton, Jr, MD, FACE Kenneth S Hershon, MD, FACE Lois G Jovanovic, MD, FACE Michael Kleerekoper, MD, FACE Jeffrey I Mechanick, MD, FACE, FACP, FACN Pasquale J Palumbo, MD, MACE Anne L Peters, MD Herbert I Rettinger, MD MBA, FACE Helena W Rodbard, MD, FACE Harvey A Rubenstein, MD, FACE John A Seibel, MD, MACE John B Tourtelot, MD, FACE, CDR, USN
Abstract
Foreword
In these clinical practise guidelines1, specific recommendations are made for determining the most effective methods of diagnosing and treating hypogonadism in adult male patients. The target populations for these guidelines include: men with primary testicular failure requiring testosterone replacement (hypergonadotropic hypogonadism); male patients with gonadotropin deficiency or dysfunction who may have received testosterone replacement therapy or treatment for infertility (hypogonadotropic hypogonadism); and aging men with symptoms relating to testosterone deficiency who could benefit from testosterone replacement therapy. Initial hormonal evaluation generally consists of a testosterone determination, in conjunction with a free testosterone or sex hormone-binding globulin level, in patients with clear symptoms and signs but normalrange total testosterone, follicle-stimulating hormone, luteinizing hormone, and prolactin levels. Other possible tests include semen analysis, pituitary imaging studies, genetic studies, bone densitometry, testicular ultrasonography, testicular biopsy, and specialized hormonal dynamic testing. Therapeutic options generally consist of testosterone replacement by injections, patches or topically applied gel in hypergonadotropic patients and in hypogonadotropic patients not interested in fertility. In hypogonadotropic patients interested in fertility, gonadal stimulation options can be considered, including human chorionic gonadotropin stimulation therapy, with or without human menopausal gonadotropin (or follicle-stimulating hormone), or gonadotropin-releasing hormone pump therapy. These therapies may be combined with assisted reproductive technologies such as in vitro fertilization with intracytoplasmic sperm injection, which may allow pregnancy to occur with very low numbers of sperm2.
Guidelines are systematically developed statements to assist healthcare professionals in medical decisionmaking for specific clinical conditions. Most of the content therein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable.The authors encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances.
Mission Statement
Hypogonadism is defined as inadequate gonadal function, as manifested by deficiencies in gametogenesis and/or the secretion of gonadal hormones3. Men with hypogonadal disorders have symptoms that are often denied by the patient and ignored by the physician. In addition, diagnostic evaluation and therapeutic options are poorly understood. With a longer lifespan and with advances in the treatment of cardiovascular disease, some aging men suffer from associated decreases in testosterone levels that may increase the risk of osteoporosis, sexual dysfunction, fatigue, cardiovascular disease, and mood disturbances. Prostate cancer in men remains a common problem that demands further research efforts and also is an issue in the consideration of testosterone replacement therapy. Of prime consideration is the paucity of long-term research studies on the identification of men at risk for complications related to a decreased testosterone level, optimal assessment of such patients, optimal treatment, and potential complications relating to long-term therapy.
B U S I N E S S B R I E F I N G : N O RT H A M E R I C A N P H A R M A C O T H E R A P Y
AACE Hypogonadism Guidelines Update

These guidelines on the evaluation and treatment of hypogonadism in adult male patients represent not only a source of guidance for healthcare professionals but also an appeal to clinicians to increase their awareness of the problem and to discuss these issues with their at-risk patients.With growing awareness and increased research efforts, both the duration and the quality of life for aging men will improve.
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practise for the Evaluation and Tr e a t m e n t o f H y p o g o n a d i s m i n A d u l t Male Patients 2002 Update4
General Manifestations
acute onset of hypogonadism); and poor ability to concentrate. The risk of osteoporosis and attendant fractures is increased. Many cases of hypogonadism are diagnosed during the course of infertility evaluations.
Evaluation
A comprehensive history should be elicited and a complete physical examination should be performed to help determine the cause and extent of the hypogonadism.
Histor y
Hypogonadism may manifest itself with testosterone deficiency, infertility, or both conditions. Symptoms of hypogonadism depend primarily on the age of the male patient at the time of development of the condition. Hypogonadism is often unrecognized before the age of puberty, unless it is associated with growth retardation or other anatomic or endocrine abnormalities. When hypogonadism develops before the age of puberty, the manifestations are those of impaired puberty: small testes, phallus, and prostate; scant pubic and axillary hair; disproportionately long arms and legs (from delayed epiphyseal closure); reduced male musculature; gynecomastia; and persistently high-pitched voice. Postpubertal loss of testicular function results in slowly evolving, subtle, clinical symptoms and signs. In aging men, these symptoms and signs may be difficult to appreciate because they are often attributed to getting older. The growth of body hair usually slows, but the voice and the size of the phallus usually remain unchanged. Prostate size may decrease in hypogonadal men, but the amount of change is related to the severity of testosterone deficiency. Typical, temporal hair recession and balding usually do not occur and if they did, these manifestations would not be expected to prompt a patient to seek medical attention. Patients with hypogonadism may have the following findings: progressive decrease in muscle mass; loss of libido; impotence; oligospermia or azoospermia; occasionally, menopausal-type hot flushes (with
Any history of loss of libido, sexual dysfunction, a lowvolume ejaculate, or impotence should generally be noted. A history of use of medications, herbal preparations, or home remedies and any history of possible exposure to diethylstilbestrol in utero should be elicited. A history of anosmia or hyposmia, mid-line defects, or cryptorchidism may be suggestive of Kallmanns syndrome or other types of hypogonadotropic hypogonadism. A family history may also indicate an underlying genetic basis. Primary testicular failure is usually associated with genetic syndromes such as Klinefelters syndrome or congenital disorders such as anorchism.Testicular failure may also be associated with a history of testicular trauma, certain surgical procedures in the area, cryptorchidism, mumps orchitis, and, occasionally, toxic exposures, radiation treatment or chemotherapy. A postpubertal onset of hypogonadotropic hypogonadism, generally manifesting as a loss of libido, sexual dysfunction, or impotence, should suggest the possibility of hypothalamic or pituitary disease. Evidence of other endocrine deficiencies such as central hypothyroidism or secondary adrenal insufficiency, visual field disturbances, headaches, or seizures may also be associated with pituitary tumors or other central disorders.
P hy s i c a l E x a m i n a t i o n
The amount and distribution of body hair, including beard growth, axillary hair, and pubic hair, should be noted, as should the presence of a male pattern escutcheon.The ethnic origin of the patient should be considered in this assessment.Any decrease in body hair or beard growth should also be noted.The presence and degree of gynecomastia should be recorded. The presence of galactorrhea would suggest pronounced hyperprolactinemia, usually associated with some degree of hyperestrogenism.
Reference Section
The testes should be measured (length and width) by using a Prader orchidometer or calipers. Some testicular disorders may selectively affect production of sperm without influencing production of testosterone. These disorders may sometimes be detected by a careful physical examination, including a determination of the testicular size and consistency. Because approximately 85% of testicular mass consists of germinal tissue, a reduced germinal cell mass would be associated with a reduced testicular size and a soft consistency. Testicular growth is a reliable index of pubertal progression in peripubertal boys, in whom hypogonadism may frequently be difficult to distinguish from delayed puberty5.Although ethnic and racial origin may influence testicular size, approximate ranges are as follows: prepubertal testes are 34mL in volume and <2cm long; peripubertal testes are 415mL in volume and >2cm long; and adult testes are usually 2030mL in volume and 4.56.5cm long x 2.83.3cm wide. Testicular consistency should be noted. If the germinal epithelium was damaged before puberty, the testes are generally small and firm. If postpubertal damage occurred, the testes are usually small and soft6. On examination of the scrotum, the presence of any masses or varicoceles should be noted for further evaluation. For assessment of any potentially significant varicocele, the patient should be asked to perform a Valsalva maneuver and the scrotal contents should be examined. In prepuberty, the length of the stretched penis is about 48cm and the width is less than 2cm in a flaccid state. In the adult, the length of the penis ranges from about 1017cm and the width in the flaccid state is more than 3cm. With the prepubertal onset of hypogonadism, the stature may assume eunuchoid proportions with a crown-to-pubis over pubis-to-floor ratio of less than 0.92 and an arm span more than 3cm greater than the height. These proportions vary according to racial and ethnic background. A non-palpable prostate suggests low testosterone levels. A prostate that is normal for age suggests reasonably normal testosterone levels. Of note, an enlarged prostate may not diminish substantially if once-normal testosterone levels have decreased.
L a b o ra t o r y S t u d i e s Te s t o s t e ro n e
Testosterone levels vary from hour to hour; periodic declines below the normal range can occur in some otherwise normal men7. An overall diurnal rhythm is also present, the highest levels of circulating testosterone occurring during the early morning hours. Therefore, testosterone levels should be determined in the morning and studies should be repeated in patients with subnormal levels, especially those with no definite signs or symptoms of hypogonadism. Testosterone circulates principally in bound form, mainly to sex hormone-binding globulin (SHBG) and albumin. It binds tightly to SHBG and is not biologically available, whereas the testosterone fraction associated with albumin is bound weakly and can dissociate to become free, active testosterone8. In young adult men, only about 2% of testosterone is in the free form, 30% is bound tightly to SHBG, and 68% is bound weakly to albumin9. Although a testosterone determination is the threshold test in the evaluation of suspected male hypogonadism, the total testosterone concentration may be within the normal range in men with primary testicular disorders such as Klinefelters syndrome. Low production of testosterone and increased estradiol stimulate the production of SHBG by the liver.The increased level of SHBG results in higher circulating total testosterone than would otherwise be present with low circulating free testosterone. An increased SHBG level may also be associated with hyperthyroidism, liver disease, severe androgen deficiency or estrogen excess. SHBG levels increase about 1% per year as men age. Male patients with hypogonadism often have high SHBG levels because of low serum testosterone levels and enhanced production of estradiol because of increases in intratesticular aromatization. Therefore, if the clinical findings indicate that hypogonadism is present and the total testosterone levels are normal or borderline low, the level of SHBG or free testosterone by equilibrium dialysis should be determined. The measurement of total testosterone values can be enhanced in borderline cases with the measurement of SHBG levels. Free testosterone assays are method-dependent and may be difficult to interpret. Because albumin binds testosterone weakly, the amount of free testosterone measured will vary with the technique. Determination of the serum testosterone concentration by equilibrium dialysis is usually more reliable. Equilibrium dialysis-free testosterone measurements are generally available and used to determine the amount of testosterone not bound to SHBG or albumin. Free

testosterone measured by an analog displacement assay is probably not reliable and should not be used. An important research goal is to establish a consistent method for determining free testosterone levels and to verify the results so that these levels can be more widely used and trusted. This issue arises frequently in the assessment of older men with impotence, in whom free testosterone or total testosterone interpreted with SHBG levels may be useful for determining the threshold of therapy1012. Conversely, a low testosterone level may also be misleading under some circumstances. Slightly subnormal levels of total testosterone may occur in men with low levels of SHBG and normal circulating levels of free testosterone. A low SHBG level may be associated with hypothyroidism, obesity, or acromegaly. Determination of the level of SHBG or free testosterone by equilibrium dialysis may be helpful for clarifying the underlying disorder, especially when the clinical findings are not suggestive of hypogonadism13. Another alternative is the use of the free testosterone index. The free testosterone index is the testosterone level (in nanomoles per liter) divided by the SHBG (in nanomoles per liter)14.
G o n a d o t ro p i n s
hormone (GnRH) testing by an endocrinologist, may help in the further assessment of these patients. Both FSH and LH are secreted in short pulses. FSH has a longer half-life than does LH and is more likely to provide adequate results on a single blood sample. In addition, most patients with progressive hypogonadism will have increased FSH levels well before LH levels increase. Because LH has a shorter half-life than does FSH, errors may be introduced in measurements made on single samples. Pooled samples for LH taken 20 to 30 minutes apart are more accurate than single-sample determinations, albeit less convenient. Persistent borderline values may be evaluated further with dynamic endocrine testing.These tests may include the GnRH stimulation test, the clomiphene stimulation test, and the human chorionic gonadotropin (hCG) stimulation test. These specialized, dynamic studies should be conducted and interpreted by an endocrinologist and may have limited clinical value.
D y n a m i c Te s t s
G n R H S t i mu l a t i o n Te s t
If a low testosterone level has been established, further laboratory testing is used to determine whether the hypogonadism is related to a primary testicular disorder (hypergonadotropic hypogonadism) or to pituitary disease (hypogonadotropic hypogonadism).The primary feature of hypogonadotropic hypogonadism is the failure of a reciprocal increase in gonadotropins in the setting of a substantially decreased testosterone level. In patients with signs and symptoms indicative of hypogonadism, determining luteinizing hormone (LH) and folliclestimulating hormone (FSH) levels together with the initial testosterone level is usually most efficient. FSH and LH may have variable biologic activity, depending on their carbohydrate content. Unlike standard radioimmunoassays, highly sensitive, two-site radioimmunometric assays for gonadotropins yield results that generally correlate well with biologic assays. Because the biologic-to-radioimmunologic ratio of activity of gonadotropins may vary according to age and disease states, the15 most accurate results will be obtained with these highly sensitive assays9. Currently, many assays for gonadotropins lack the sensitivity to detect values below the normal range, unlike the modern thyrotropin assays for thyroid disease. Additional studies, such as gonadotropin-releasing
In the GnRH stimulation test16,17, intravenous injection of 100g of GnRH causes serum LH levels to increase between threefold and sixfold during a period of 30 to 45 minutes and FSH levels to increase between 20% and 50%. Various degrees of primary testicular failure cause higher than expected peak values for LH and FSH. Men with hypothalamic or pituitary disease may have a reduced or normal response that is often inadequate for distinguishing between a pituitary and a hypothalamic disorder. If the pituitary gland is primed with repeated doses of GnRH, this stimulation test may provide a more sensitive and reliable result.
C l o m i p h e n e S t i mu l a t i o n Te s t
In the clomiphene stimulation test, 100mg of clomiphene citrate are given for five to seven days as an evocative test of the hypothalamic-pituitary axis. Clomiphene acts by interrupting the negative feedback loop and thereby stimulating release of gonadotropin from the pituitary.A doubling of LH and a 20% to 50% increase in FSH are normal results indicative of an intact hypothalamic-pituitary response18.
h C G S t i mu l a t i o n Te s t
Various protocols are used for hCG stimulation testing. In general for postpubertal male patients, a single dose of hCG (5,000 international units (IU) taken intramuscularly) is administered and pre-therapy and
Reference Section
72-hour, post-therapy testosterone measurements are conducted (some protocols use 1,000 to 4,000IU of hCG, or multi-day dosing)19.
P ro l a c t i n L eve l
interventions to be based on any deterioration in bone density that may occur over time. Such baseline studies are especially important in men treated for prostate cancer and rendered hypogonadal. In addition to addressing the underlying condition, treatment options to maintain bone mass may include testosterone therapy (but not in the setting of prostate cancer) or bisphosphonates. At present, alendronate has been approved by the US Food and Drug Administration (FDA) for use on osteoporosis in male patients. In addition, therapy should include sufficient calcium, exercise, and vitamin D. Anabolic agents such as parathyroid hormone may become therapeutic options in the future for men with osteoporosis. Regardless of treatment, bone density studies should be repeated in one to two years to determine whether bone mass is being appropriately maintained22.
Pituitar y Imaging
In men with acquired hypogonadotropic hypogonadism, who usually have a reduced libido and impotence, a prolactin level should be determined to evaluate for the presence of a prolactinoma or other cause of hyperprolactinemia. High prolactin levels can reduce GnRH and testosterone levels. In addition, a high prolactin level can reduce libido and potency even in men treated with therapeutic doses of testosterone. About 5% of men who complain of impotence will have an increased prolactin level20. Further endocrinologic evaluation with magnetic resonance imaging (MRI) scanning of the pituitary gland is indicated for unexplained hyperprolactinemia.
Semen Analysis
A semen analysis17 is the primary test to assess the fertility potential of the male patient. Semen should be collected by masturbation after two to five days of abstinence and evaluated within two hours. Variability between specimens is common; with low or borderline samples, follow-up examinations evaluating three or more samples should be carried out over a three-month period. A fertile sample is usually associated with a motility of more than 50% and a sperm count that exceeds 20 million/mL21. In general, semen volume should range from 1.5mL to 6mL. Morphologic features should be examined for abnormalities. A fructose test should be carried out on a semen sample showing azoospermia. Because fructose is secreted by the seminal vesicles, absence of fructose may indicate a complete obstruction of the ejaculatory ducts or a congenital absence of vasa deferentia and both ejaculatory ducts. Most often, a semen analysis is conducted in an otherwise asymptomatic man during the course of an infertility evaluation. For such an assessment, a semen analysis should be taken early to determine appropriate further evaluation and therapeutic options.
Other Studies
Bone Densitometr y
In cases of acquired hypogonadotropic hypogonadism (low testosterone with low-normal FSH and LH levels) not clearly attributable to a specific cause, pituitary imaging studies with MRI or computed tomography may be needed to evaluate for structural lesions in the hypothalamic-pituitary region. MRI generally provides better pituitary images, but bony changes in the sella may be better characterized by computed tomography. In general, MRI conducted both with and without a contrast agent is recommended as the initial pituitary imaging study in patients requiring delineation of a pituitary pathologic condition. Although no published studies have indicated clearly a particular level of testosterone in the setting of hypogonadotropic hypogonadism that should prompt pituitary evaluation, a total testosterone concentration of 150 nanograms per deciliter (ng/dL) or below has been considered a reasonable level at which to pursue pituitary imaging, even in the absence of other symptoms. Certainly, other symptoms suggestive of pituitary disease necessitate appropriate further evaluation. A considerable proportion of aged men with hypogonadism of unknown cause have a central origin for this disorder. Possible contributing factors may include aging itself, medications, and chronic illness. Further research in this area is clearly warranted.
Genetic Studies
Because hypogonadism frequently results in low bone density and increased fracture risk, baseline hip and spine bone densitometry studies should be performed to assess the initial situation and allow future
Patients with hypergonadotropic hypogonadism and impaired pubertal development associated with small, firm testes and often with gynecomastia are likely to have Klinefelters syndrome or a variant. Classically, a buccal smear was taken to establish the diagnosis by revealing Barr bodies.We currently recommend genetic karyotype

testing to confirm the diagnosis in a patient with these findings at initial assessment. Fluorescent in situ hybridization studies increase the sensitivity of detecting Klinefelters syndrome associated with mosaicism.
Te s t i c u l a r B i o p s y a n d S c ro t a l E x p l o ra t i o n
Since the advent of sensitive FSH assays, germinal cell function is now most often assessed through the FSH assay alone rather than testicular biopsy. In general, however, men with azoospermia, normal FSH levels, and normal testicular size should usually undergo testicular biopsy and scrotal exploration to determine whether a germinal cell abnormality, an obstruction or a congenital abnormality of the vasa is present.
Te s t i c u l a r U l t ra s o n og ra p hy
These patients have azoospermia, but those with mosaicism may have some spermatogenesis and may produce some pregnancies early during their reproductive lives.Virilization may begin with puberty, but frequently fails to progress. Gynecomastia is often present and frequently necessitates surgical therapy for cosmetic reasons or because of concerns about breast cancer, which occurs with an increased incidence in Klinefelters syndrome. The high levels of LH and FSH stimulate testicular aromatase activity; as a result, estradiol levels are increased. Bone density is significantly lower than for age-matched, male control subjects. Learning disabilities are often present, as manifested by dyslexia and attention deficit disorder. Auto-immune disorders are present with increased frequency in patients with Klinefelters syndrome and may respond favourably to testosterone therapy25.
Other Genetic Syndromes
4 7 , X Y Y S y n d ro m e
Testicular ultrasound examination should be conducted in patients with clinical findings suggestive of a scrotal or testicular mass.
Differential Diagnosis and Special Considerations
The differential diagnosis of hypogonadism includes a large and diverse group of disorders affecting the testicles directly, or affecting hypothalamic-pituitary regulation of the testes. The clinical setting, history, physical examination, and clinical judgment will, to a large degree, determine which possible etiologic factors are present. These guidelines summarize the various disorders, but are not intended to be comprehensive23.
Hypergonadotropic Hypogonadism
The 47,XYY karyotype, which occurs in about 0.1% of males, may be associated with hypogonadism. In some men with this disorder, aggressive behaviour has been noted. Affected patients may have azoospermia in association with maturation arrest of the germinal epithelium. Usually, serum FSH levels are increased, but Leydig cell function is normal, as are testosterone and LH levels.
D y s g e n e t i c Te s t e s
Patients with hypergonadotropic hypogonadism may have some or all of the following characteristic findings: hypogonadism; increased FSH level; increased LH level; low testosterone level; and/or impaired production of sperm.
Dysgenetic testes may occur in conjunction with mosaicism; the patient may have an XO karyotype, a mixed XO/XY karyotype, or pure XY with gonadal streaks. Occurrence of pure gonadal dysgenesis in association with an XY karyotype and gonadal streaks26 imposes a substantial risk of gonadoblastoma, which necessitates gonadectomy. Such patients generally have genital ambiguity.
A n d rog e n R e c e p t o r D e f e c t s
K l i n e f e l t e r s S y n d ro m e
Klinefelters syndrome is caused by the presence of an extra X chromosome in the male karyotype and occurs in about one in every 400 men9. The most common karyotype is 47,XXY and mosaicism is sometimes present24. Men with Klinefelters syndrome classically have small (less than 2.5cm), firm testes, gynecomastia, eunuchoid habitus, and increased gonadotropin levels. Although production of testosterone is low, high levels of SHBG may result in normal-range testosterone levels in about 40% of patients with Klinefelters syndrome.
Patients with androgen receptor defects have an XY genotype and variable phenotype, depending on the degree of receptor defect. Such syndromes include testicular feminisation, Reifensteins syndrome, and other partial defects, as discussed in the following paragraphs.
Te s t i c u l a r Fe m i n i z a t i o n
The most severe form of androgen resistance syndrome is testicular feminization. Patients with testicular feminization have a female phenotype but a blind vaginal pouch. Testosterone receptors are non-
Reference Section
functional or absent. Laboratory testing shows normal to high male range testosterone and increased gonadotropin levels.The testes should be removed after puberty because of an increased risk of a malignant lesion due to cryptorchidism. Administration of testosterone yields no response.
R e i f e n s t e i n s S y n d ro m e
In Reifensteins syndrome, patients have a male phenotype with variable pseudohermaphroditism. A partial androgen receptor defect is present; testosterone and gonadotropin levels are increased. Abdominal testes should be removed because of the risk of a malignant lesion. If hypospadias is present, surgical correction of the genitalia may be needed. Any significant gynecomastia may also need surgical correction. Patients may respond to high doses of testosterone.
O t h e r S y n d ro m e s
Some male patients with gynecomastia or oligospermia may have partial androgen insensitivity, in association with mild increases in testosterone and gonadotropin levels.
5- Reductase Deficiency
most testes ultimately descend. Thus, the one-year incidence is about 0.8%. Because normal testicular descent requires normal pituitary function and dihydrotestosterone levels, the incidence of cryptorchidism is increased in patients with Kallmanns syndrome. Problems associated with the management of cryptorchidism include distinguishing between cryptorchidism and retractile testes and recommending medical treatment with hCG or surgical therapy in an infant28. Generally, the objective is to bring the undescended testicle into the scrotum before one to two years of age to improve fertility potential. Because a slight risk of a malignant lesion is associated with undescended testicles, surgical placement into the scrotum offers the opportunity for thorough examination. In prepubertal boys, treatment with hCG may be used for four weeks to determine whether testicular descent occurs before operative intervention is considered. Discussion of these problems is beyond the scope of these guidelines; appropriate specialty consultation should be obtained.
Va n i s h i n g Te s t e s S y n d ro m e ( C o n g e n i t a l A n o r c h i s m o r P re p u b e r t a l F u n c t i o n a l C a s t ra t e )
An autosomal recessive condition, 5- reductase deficiency syndrome is associated with an XY genotype. Affected patients, however, have female genitalia until puberty, when increasingly male features develop. The diagnosis is based on clinical manifestations and an increased testosterone-todihydrotestosterone ratio, both after puberty and in response to hCG before puberty. Sexual assignment is an issue and patients may need corrective surgical procedures that necessitate specialty consultation.
M y o t o n i c D y s t ro p hy
The initial manifestation of the vanishing testes syndrome is sexual immaturity in a male patient. The cause is unclear, but the syndrome may be due to testicular torsion during fetal life after sufficient testosterone exposure to produce masculinization of the reproductive tract. Impalpable testes suggest the possibility of cryptorchidism. FSH and LH levels are increased, and testosterone levels are low. If the LH levels are only minimally increased, hCG stimulation testing of the gonad should be done.With vanishing testes syndrome, no response would be demonstrated. A response to hCG stimulation would raise the possibility of intraabdominal testes, which would necessitate further evaluation because of the potential for malignant transformation. In this setting, MRI is recommended to assess the possibility of a retained, intra-abdominal, dysgenetic gonad, because this would be associated with an increased risk of a malignant lesion and would necessitate removal.
H e m o c h ro m a t o s i s
Classically, myotonic dystrophy is an autosomal dominant disorder, characterized by hypogonadism, muscle weakness, and frontal balding, that occurs only in male patients. Recent studies have demonstrated repeat sequences of CTG in an untranslated region of the dystrophia myotonica-protein kinase (DMPK) gene in many of these patients, but the disorder seems to be genetically and phenotypically heterogeneous27. Testicular failure usually occurs after age 40 years; thus, patients often have children at risk for the disease. Testosterone levels may be variably decreased in the setting of azoospermia and high gonadotropin levels.
Cr yptorchidism
Unilateral or bilateral cryptorchidism can occur. The incidence of this condition is 3% to 4% at birth, but
Iron overload may lead to primary gonadal failure or sometimes hypothalamic-pituitary dysfunction that results in secondary gonadal failure29. The diagnosis is made in the setting of associated findings of hemochromatosis in conjunction with an increased ferritin level and is generally confirmed with a liver or bone marrow biopsy.

E x t e r n a l Te s t i c u l a r I n s u l t s Tra u m a K a l l m a n n s S y n d ro m e
The patient may have a history of direct traumatic injury.Testicular torsion sometimes is associated with a bell-clapper abnormality, in which the testes lie horizontally because of incomplete closure of the surrounding tissues.
Mumps Orchitis
In patients with post-pubertal mumps, a 25% risk of orchitis exists. More than 50% of those patients with orchitis will be infertile. Increased FSH concentrations and oligospermia or azoospermia are present. Mumps orchitis can progress to produce low testosterone and high LH levels in some men. Unilateral, testicular atrophy can progress to bilateral failure over the years.
R a d i a t i o n Tre a t m e n t o r C h e m o t h e ra py
Classic Kallmanns syndrome is a congenital disorder inherited as a sporadic condition or generally as an X-linked, recessive trait manifesting as prepubertal hypogonadism.The incidence of this syndrome is about 1 in 10,000 male births. Low testosterone levels are present because of an impaired release of LH and FSH as a result of variable GnRH deficiency. LH and FSH are released in response to priming followed by stimulation with GnRH. The gene on the X chromosome for classic Kallmanns syndrome and associated anosmia has been identified and cloned30. Autosomal recessive and autosomal dominant variants of hypogonadotropic hypogonadism also exist and are referred to as idiopathic hypogonadotropic hypogonadism. Classically, Kallmanns syndrome is associated with anosmia as a result of defective development of the olfactory tract in the brain. The GnRH-containing neurons originate in the developing olfactory tract and therefore do not develop properly in this syndrome9. This defective development of the olfactory tract can be diagnosed by MRI scanning. In some cases, other defects such as cerebellar dysfunction, red-green color blindness, cleft palate, and congenital deafness are present31. Cryptorchidism may occur because gonadotropins contribute to normal testicular descent. The prepubertal testes in patients with Kallmanns syndrome tend to be larger than in patients with Klinefelters syndrome and are appropriate up until puberty, in as much as normal initial amounts of germinal tissue are present. Partial pubertal development may be present in patients with partial defects; thus, Kallmanns syndrome may be difficult to distinguish from delayed puberty up through the teenage years. Once a patient with Kallmanns syndrome has been identified, other family members at risk (on the basis of their mode of inheritance) should be assessed, if possible.
O t h e r R e l a t e d S y n d ro m e s
With irradiation or chemotherapy, testicular exposure can occur from treatment of another disease or inadvertently. A dose-dependent recovery potential and a variable Leydig cell dysfunction have been noted. Pretreatment sperm banking is possible if future fertility is desired and sperm counts are normal.
A u t o - i m mu n e S y n d ro m e s
Anti-Leydig cell, antibody-associated disorders, or conditions associated with anti-sperm antibodies are autoimmune syndromes related to hypogonadism. These syndromes are poorly characterized and further research is needed to determine diagnostic criteria and possible treatment options.
S e r t o l i - c e l l - o n l y S y n d ro m e
The absence of germ cells in patients with small testes, high FSH levels, azoospermia, and normal testosterone levels should suggest the presence of Sertoli-cell-only syndrome. The diagnosis can be made only by testicular biopsy. The presence of Leydig cell hyperplasia is common and may be responsible for high serum estradiol levels. The cause of this syndrome is currently unknown.
H y p og o n a d o t ro p i c H y p og o n a d i s m
The condition of hypogonadotropic hypogonadism is generally associated with the following findings: low or low-normal FSH level; low or low-normal LH level; and low testosterone level.
Congenital, hypogonadotropic syndromes are associated with secondary hypogonadism and other somatic findings. Prader-Willi syndrome is characterized by hypogonadism, short stature, mental retardation, hypotonia at birth, and obesity. LaurenceMoon-Bardet-Biedl syndrome is an autosomal recessive trait characterized by mental retardation, retinitis pigmentosa, polydactyly, and hypogonadism. These syndromes may be due to a hypothalamic deficiency of GnRH.
Reference Section
Fe r t i l e E u nu c h S y n d ro m e
Hypogonadotropic hypogonadism in patients who have modest FSH secretion and selective LH deficiency is known as the fertile eunuch syndrome. Fertility may be present in some of these patients. These men usually respond to hCG therapy.
P i t u i t a r y D i s o rd e r s
decreased muscle mass, fatigue, increased risk of myocardial infarction35, and decreased bone mass in conjunction with osteoporosis. Some early studies indicated that the problem may be related to coexisting conditions, but more recent evidence supports the view that an age-related decline in testicular function may occur with associated symptoms and often responds to testosterone replacement therapy36,37. Measurements of SHBG in conjunction with total testosterone are usually needed to demonstrate the abnormality.Age-related declines in free testosterone, as measured by equilibrium dialysis, are more rapid than the decreases in total testosterone. The SHBG levels increase with advancing age, probably in relation to higher serum estradiol levels from increased adipose tissue. Often, the FSH and LH levels are mildly increased, an indication that a primary testicular disorder may be present in conjunction with a secondary abnormality in LH burst frequency38. Dynamic testing may disclose more subtle abnormalities of hypothalamic function. The circadian variation in serum testosterone levels, with higher values in the morning, is generally lost with aging. Data from long-term research studies is needed to clarify the criteria for therapeutic considerations in aging men. Short-term research studies have demonstrated that testosterone replacement treatment may result in improved lean body mass, increased hematopoiesis, decreased low-density lipoprotein (LDL) levels in conjunction with a constant ratio of LDL to high-density lipoprotein (HDL), improved libido, and improved well-being in older men with low testosterone levels. Generally, prostate size and prostatespecific antigen (PSA) levels do not change in comparison with otherwise normal men, but PSA levels have been found to increase in some men39. Men with symptomatic hypogonadism and a total testosterone level of less than 200ng/dL may be potential candidates for therapy, although no specific recommendations have been established at this time. Some studies have used 2.5 standard deviations below the mean testosterone values for young normal male subjects as the cut-off point for the initiation of therapy, resulting in intervention at values of about 319ng/dL40. With the use of this guideline, approximately 30% of men beyond 75 years of age would have testosterone values below this hypogonadism threshold. In general, if the potential benefit exceeds the potential risk, then the patient may be a candidate for therapy. The lack of knowledge about the exact nature of the benefit and risk remains the main problem.
Acquired hypogonadotropic hypogonadism may indicate the presence of pituitary insufficiency or a pituitary tumor. Unless the reason for the pituitary defect is clear, imaging studies of the pituitary gland and the hypothalamus are indicated to determine whether a tumor or an infiltrative disorder is present. Metastatic tumors, granulomas, abscesses, and hemochromatosis may also be discovered. Hyperprolactinaemia is a potential cause of hypogonadotropic hypogonadism and generally manifests itself with a low libido and impotence. A serum prolactin level should be determined in men with acquired hypogonadotropic hypogonadism. High prolactin levels are usually associated with a prolactinoma, but certain medications may also cause hyperprolactinemia. Hypogonadotropic hypogonadism from pituitary disease may also occur with granulomatous and infiltrative disorders, cranial trauma with or without pituitary stalk transection, irradiation, and hypophysitis.
H e m o c h ro m a t o s i s
See earlier discussion of hemochromatosis in Hypergonadotropic Hypogonadism section.

S e r i o u s I l l n e s s , A I D S a n d S t re s s
Transient hypogonadotropic hypogonadism may occur in patients with serious disorders or malnutrition32. AIDS may be associated with low testosterone levels and generally low gonadotropin levels (consistent with hypothalamic-pituitary involvement). In some patients with AIDS, gonadotropin levels are increased (consistent with testicular disease)33.
Aging
Considerable controversy exists over the concept of a male climacteric or andropause34. Growing evidence indicates that some aging men have a reduced production of testosterone associated with decreased libido, impotence, decreased growth of body hair,

Therapy
Goals of Therapy
To R e s t o re S ex u a l F u n c t i o n , L i b i d o , We l l b e i n g a n d B e h a v i o r
testosterone levels less than 300ng/dL). Hypogonadism was present in up to 20% of men with vertebral crush fractures, even though many of these men did not have other clinical features of hypogonadism. In adolescent male patients with hypogonadotropic hypogonadism, testosterone therapy increases bone mineral density in comparison with that in male patients with hypogonadism not receiving testosterone45,46. In men with prepubertal-onset hypogonadotropic hypogonadism, however, diminished bone mass may be only marginally improved by testosterone replacement47.
Possibly to Normalize Growth Hormone Levels in Elderly Men
Many studies have been undertaken to evaluate the effects of testosterone therapy on sexual function and wellbeing in men with hypogonadism41. Impaired sexual behavior and mood disturbances seem to occur below a certain threshold of circulating testosterone levels and most studies have demonstrated improved function with testosterone replacement. In studies of testosterone treatment of men with hypogonadism, investigators have found that therapy resulted in increased sexual interest and an increased number of spontaneous erections. On psychological testing, the men with untreated hypogonadism tended to score high on depression, anger, fatigue, and confusion scales. Hormonal replacement diminished most of these traits, but although the depression score improved, it remained more of a problem in men with hypogonadism than in male control subjects42. Further long-term studies are clearly needed in this area to establish definite criteria for therapy and response in borderline cases. Notably, erectile dysfunction associated with hypogonadism may not improve after adequate androgen replacement if other secondary causes for erectile dysfunction are present. For additional information, see the American Association of Clinical Endocrinologists Clinical Practice Guidelines for the Evaluation and Treatment of Male Sexual Dysfunction43. With the onset of hypogonadism before puberty, an initial low dose of testosterone should be used to avoid acute priapism, adverse psychological effects, and aggressive behavior.
To P r o d u c e a n d M a i n t a i n V i r i l i s a t i o n
In comparison with normal men, those with hypogonadism have significantly reduced mean growth hormone pulse amplitude but normal pulse frequency. Patients with adult-onset growth hormone deficiency also have increased cardiovascular-related mortality48. Testosterone treatment results in a significant increase in 24-hour mean serum growth hormone value and mean growth hormone pulse amplitude. Perhaps testosterone has an important role in the control of growth hormone secretion in adulthood and testosterone therapy may have a No specific positive clinical influence49. recommendations on this issue are possible until further research clarifies the potential risks and benefits of therapy.
Potentially to Affect the Risk of Cardiovascular Disease
Orally administered, alkylated androgens are nonaromatizable and result in increased LDL and decreased HDL levels, which may increase cardiovascular risk25,50,51. Unlike orally administered, alkylated androgen preparations, testosterone is aromatised to estrogen. In men with hypogonadism treated with replacement doses of testosterone, total cholesterol and LDL levels may modestly decrease in conjunction with minimal change in HDL; thus, investigators have speculated that the risk of cardiovascular disease may be higher in men with hypogonadism not receiving testosterone replacement52. Testosterone replacement therapy in men is not associated with major adverse lipid changes53; in fact, endogenous testosterone and administration of exogenous testosterone may lower the atherogenic Lp(a) lipoprotein levels54. Other studies suggest that testosterone replacement in men with hypogonadism
Secondary sex characteristics such as increased muscle mass, beard growth, growth of pubic and axillary hair, and phallus growth improve with testosterone therapy.
To O p t i m i z e B o n e D e n s i t y a n d Prevent Osteoporosis
In a study of elderly male nursing home residents, the incidence of hip fracture was between 5% and 15%44. Of those residents who had sustained a prior hip fracture, 66% were found to have hypogonadism (serum
10
Reference Section
may be associated with adverse lipid effects and yet other studies have reported indeterminate findings34. Other cardiovascular effects, apart from changes in lipids, may be attributable to testosterone replacement therapy. A potential risk of testosterone therapy is the propensity of testosterone to increase platelet aggregation and thrombogenicity55. Currently, whether testosterone replacement therapy in men with hypogonadism increases, decreases, or has a neutral effect on cardiovascular risk remains uncertain. Long-term prospective research must be conducted to assess the role of endogenous testosterone and testosterone replacement therapy on cardiovascular risk in men. No specific recommendations on this issue are possible until further research clarifies the potential risks and benefits of therapy.
To R e s t o r e F e r t i l i t y i n C a s e s o f Hypogonadotropic Hypogonadism
and 800ng/dL) and physiologic range dihydrotestosterone and estradiol levels, which would allow optimal virilization and normal sexual function. Testosterone therapy can be used in the male patient with hypogonadism who is not interested in fertility or not able to achieve fertility. In late teenage male patients with delayed puberty, testicular size should be monitored for evidence of the onset of puberty. In this setting, short-term, low-dose testosterone therapy should be withdrawn to determine whether spontaneous puberty is occurring. The following preparations of testosterone have been approved by the FDA for clinical use: long-acting, intramuscular preparations; short-acting, intramuscular preparations; scrotal patches; transdermal patches; transdermal gel; and orally administered agents.
See subsequent sections relating to therapy for hypogonadotropic hypogonadism.

C o n t r a i n d i c a t i o n s t o Te s t o s t e r o n e , GnRH and Gonadotropin Therapy
Testosterone replacement, pulsatile GnRH therapy, and gonadotropin therapy are contraindicated in men with prostate cancer, male breast cancer or untreated prolactinoma. Treatment with these medications can stimulate tumor growth in androgendependent neoplasms. Careful examination of the male breast and prostate is required initially and at follow-up visits. In addition to prostate examination, baseline and followup PSA levels should be determined in older men at increased risk for prostate cancer. Men with symptomatic prostatism should undergo evaluation and treatment for this problem before testosterone replacement therapy is considered. Sleep apnea and polycythemia, which may cause hyperviscosity, are relative contraindications to the use of testosterone therapy. Testosterone treatment will tend to reduce sperm counts and testicular size and should not be used in men currently seeking fertility.
Te s t o s t e r o n e T h e r a p y i n A d u l t M a l e Patients with Hypogonadism
Orally administered testosterone is quickly metabolized by the liver and cannot achieve sufficient blood levels over time to be useful. The orally administered, alkylated androgen preparations currently available in the US are generally not recommended because of poor androgen effects, adverse lipid changes and hepatic side effects such as hemorrhagic liver cysts, cholestasis, and hepatocellular adenoma25. In Europe, testosterone undecanoate may be a more acceptable oral alternative, but erratic testosterone levels, frequent dosing, and occasional gastrointestinal side effects may limit the usefulness of this preparation in the US. Reformulation of this preparation with testing in the US and elsewhere is currently under way. Injectable testosterone pellets are sometimes used and further study may prove them to be suitable for many men. For patients with hypogonadotropic hypogonadism wishing fertility, hCG with or without human menopausal gonadotropin (FSH) or pulsatile GnRH therapy and hCG with or without assisted reproduction are options.
P a r e n t e r a l Te s t o s t e r o n e P r e p a r a t i o n s
11
Ideally, testosterone therapy should provide physiologic range serum testosterone levels (generally between 280
Testosterone enanthate and testosterone cypionate are long-acting testosterone esters suspended in oil to prolong absorption. Peak levels occur about 72 hours after intramuscular injection and are followed by a slow decline during the subsequent one to two weeks56. For complete androgen replacement, the regimen should be

between 50mg and 100mg of testosterone enanthate or cypionate administered intramuscularly every seven to 10 days, which will achieve relatively normal levels of testosterone throughout the time interval between injections57. Longer time intervals are more convenient, but are associated with greater fluctuations in testosterone levels. Higher doses of testosterone produce longer-term effects but also higher peak levels and wider swings between peak and nadir circulating testosterone levels; the result is fluctuating symptoms in many patients58. The use of 100mg to 150mg of testosterone every two weeks is a reasonable compromise. Use of 300mg injections every three weeks is associated with wider fluctuations of testosterone levels and is generally inadequate to ensure a consistent clinical response.With use of these longer interval regimens, many men will have pronounced symptoms during the week preceding the next injection. In such instances, a smaller dose at closer intervals should be tried. As a guide, testosterone levels should be above the lower limit of normal, in the range of 250ng/dL to 300ng/dL, just before the next injection59. Excessive peak levels and side effects should also be monitored and used to adjust the dosing regimens. When full androgen replacement is not required, patients should receive lower doses of testosterone. One such category includes adult male patients with a prepubertal onset of hypogonadism who are going through puberty for the first time during therapy and who frequently require psychological counseling, especially when a spouse is involved as well. In these patients, testosterone therapy should be initiated at 50mg every three to four weeks and then gradually increased during subsequent months, as tolerated, up to full replacement within one year. Men with appreciable benign prostatic hypertrophy who have hypogonadism and symptoms may be given 50mg to 100mg of testosterone every two weeks as an initial regimen and maintained on this dosage with careful monitoring of urinary symptoms and prostate examinations; therapy can be withdrawn if necessary. Attaining a full virilization in the patient with hypogonadism may take as long as three to four years. Follow-up intervals should be between four and six months to monitor progress, review compliance, and determine whether any complications or psychological adjustment problems are present. Often, patients can learn how to administer their own injections. A spouse or significant other may also be instructed in this technique.
Tr a n s d e r m a l Te s t o s t e r o n e T h e r a p y
Tr a n s d e r m a l Te s t o s t e r o n e D e l i v e r y System Normal Skin
A testosterone patch with permeability enhancement allows testosterone delivery through normal skin. Daily evening application generally results in normal-range serum testosterone levels, which mimic the normal diurnal changes in testosterone in normal men. In contrast to the situation with use of the scrotal patch, dihydrotestosterone levels remain within the normal range60. Estradiol and bioavailable testosterone levels also remain within the normal range. Skin irritation may be a problem in some patients.Therapy consists of one to two patches applied daily to normal skin. As with scrotal patches, this treatment is more expensive than injections, but convenience of use, maintenance of normal diurnal testosterone levels, and elimination of office visits for injections may make this form of treatment useful in many patients. Testosterone levels should be monitored periodically to ensure the appropriate range is being maintained.
S c r o t a l P a t c h Te s t o s t e r o n e Deliver y System
Scrotal testosterone patches are available in 40cm2 and 60cm2 sizes, which deliver, respectively, 4mg and 6mg of testosterone daily. Scrotal skin absorbs testosterone better than does non-scrotal skin. The patch is applied to the scrotal skin after preparation of the scrotum with dry shaving.The patch is non-adhesive and a new patch is applied each morning.The testosterone levels mimic the diurnal rhythm present in normal men.Testosterone levels are generally maintained in the normal range and are usually well tolerated. These levels should be assessed in the morning before patch application to ensure that they are above the lower limit of the normal range at the nadir. If the scrotum is small or the skin surface is abnormal, absorption may be limited. Because genital skin contains high concentrations of 5-reductase, the dihydrotestosterone levels in treated patients increase initially but may return to normal in some men. In most men treated with the scrotal patch, however, these levels remain higher than normal61. The HDL-tocholesterol ratio in treated patients does not change significantly from before to after therapy62. The long-term potential effects of increased levels of dihydrotestosterone are unknown at this time, and careful monitoring of prostate growth is recommended. Further research may clarify any possible adverse effects of such increased levels occurring in men who receive this type of therapy.
12
Reference Section
The cost of using the scrotal patch exceeds that for testosterone injections, but the convenience of use may make this therapeutic option acceptable for many patients.
Tr a n s d e r m a l Te s t o s t e r o n e G e l
Transdermal testosterone in a hydroalcoholic gel for once-daily administration to the nongenital skin is available in packets labeled 2.5 G (containing 25mg of testosterone) and 5 G (containing 50mg of testosterone).After application of the gel, blood levels of testosterone seem to be constant over 24 hours and levels are adequate in most patients63. Positive effects on libido, mood by about 30 days of therapy, and muscle mass and strength by 90 to 180 days of therapy have been noted64. The gel is well tolerated and is generally associated with minimal skin irritation in comparison with testosterone patches65. The gel dries quickly after application. One potential problem is transfer of the gel from person to person if direct skin contact occurs. Transdermal testosterone use has been shown to decrease bone resorption markers and increase bone formation markers; in addition, small increases in bone density have been noted after six months of use66.
Monitoring Issues and Side Effects of Te s t o s t e r o n e T h e r a p y
men with high PSA values or significantly increasing PSA levels. Testosterone and especially dihydrotestosterone stimulates growth of the prostate and seminal vesicles. In a study that assessed the effect of exogenous testosterone administration by patch or by injection on the serum levels of PSA and prostatespecific membrane antigen in men with hypogonadism, the results demonstrated no correlation with therapy and thus no testosterone dependence of PSA or prostate-specific membrane antigen67. Testosterone treatment of men with hypogonadism also resulted in growth of the prostate and seminal vesicles, but this growth did not exceed the volumes expected in normal men68. No clear relationship has been established between testosterone replacement therapy and prostate cancer, although anecdotal reports have been published69. Men in whom symptomatic prostatism develops should undergo assessment before testosterone replacement therapy is continued. Long-term studies are needed to clarify this issue. Gynecomastia may result from the aromatization of testosterone to estradiol and changes in SHBG levels. Surgical therapy may be considered for some patients. Men with a genetic susceptibility to alopecia may note a worsening of this problem with testosterone therapy. Testosterone stimulates the bone marrow production of erythrocytes. The result is an increased hematocrit in some men, with the possibility of hyperviscosity side effects70. The hematocrit should be determined every six months for the first 18 months and then yearly thereafter if it is stable and normal.Testosterone therapy should be decreased or discontinued if the hematocrit increases to above 50%. Lipid disturbances in testosterone-treated male patients are generally not a problem because of the aromatisation of testosterone to estradiol. The ratio of HDL to total cholesterol generally remains constant. Anabolic steroids, used in oral testosterone preparations, that are not aromatized increase LDL and lower HDL levels and thus could increase cardiovascular risk. An initial lipid profile should be recorded and a follow-up profile should be obtained after six to 12 months of therapy and then yearly thereafter. Sleep apnoea may also be a problem in some men and testosterone therapy should be discontinued until the sleep apnoea problem can be adequately addressed71. The patient should be asked about fatigue during the day in addition to disordered sleep.A sleep study should be undertaken if symptoms are present. Because pharmacological use of testosterone will suppress spermatogenesis, the use of testosterone
Periodic follow-up of patients receiving testosterone therapy is needed. During the first year of such therapy, the clinical response and side effects should be monitored at three- to four-month intervals. For patients receiving testosterone injections, a serum testosterone level should be measured at the midpoint between injections to ensure that the value is near the middle of the normal range. Most patients using testosterone gel have constant blood levels of testosterone over 24 hours; thus, the time of measurement is usually not critical. The testosterone patch preparations usually yield peak serum testosterone values within four to eight hours after application. Examination of the prostate should be done routinely, along with a prostate-related symptom assessment every six to 12 months. PSA levels should be determined annually in older men receiving testosterone replacement therapy. High PSA levels should be evaluated further with a highly specific PSA assay, if available. If results are abnormal, a urologic consultation should be sought and testosterone replacement therapy should be terminated. Men receiving testosterone replacement therapy and finasteride should be considered for further evaluation even with PSA values in the upper normal range. Testosterone treatment should not be administered to
13

preparations may substantially reduce fertility in otherwise normal men. This adverse effect is often an issue with the illicit use of testosterone.
Gonadal Stimulation in Hypogonadotropic Hypogonadism
development may have testes generally smaller than 5mL. These patients usually require therapy with both hCG and human menopausal gonadotropin (or FSH) to induce spermatogenesis. Men with partial gonadotropin deficiency or who have previously (peripubertally) been stimulated with hCG may initiate and maintain production of sperm with hCG therapy only. Men with postpubertal, acquired hypogonadotropic hypogonadism who have previously had normal production of sperm can also generally initiate and maintain spermatogenesis with hCG treatment only74. Fertility may be possible at sperm counts much lower than what would otherwise be considered fertile. Counts of less than one million/mL may be associated with pregnancies under these circumstances. It is imperative that the female partner undergo assessment for optimal fertility before or concurrently with consideration of therapy in the man. Therapy with hCG is generally begun at 1,000IU to 2,000IU applied intramuscularly two to three times a week and testosterone levels should be monitored monthly to determine whether any therapeutic adjustments are needed to normalize the levels. It may take two to three months to achieve normal levels of testosterone. When normal levels of testosterone are produced, examinations should be conducted monthly to determine whether any testicular growth has occurred. Sperm counts should also be assessed monthly during a one-year period. Because of the high cost of human menopausal gonadotropin (or FSH) preparations, hCG should be the initial therapy of choice for at least six to 12 months. Use of hCG, in the absence of exogenous FSH, can often complete spermiogenesis in men with partial gonadotropin deficiency75. In general, the response to hCG can be predicted on the basis of the initial testicular volume the greater the initial testicular volume, the greater the chance of responding to hCG only76. In one study, however, investigators demonstrated that most patients will respond to hCG alone regardless of initial testicular volume77. Studies have shown that combining purified FSH and testosterone without LH or hCG does not stimulate spermatogenesis in truly hypogonadotropic men78. If spermatogenesis has not been initiated by the end of six to 12 months of therapy with hCG or LH, administration of an FSH-containing preparation is initiated in a dosage of 75IU, applied intramuscularly three times a week along with the hCG injections. After six months, if sperm are not present or are present in very low numbers (less than 100,000/mL), the human menopausal gonadotropin (or FSH) dosage can be increased to 150IU intramuscularly,
Because gonadotropin or GnRH therapy is effective only in hypogonadotropic hypogonadism, this diagnosis must be firmly established before consideration of therapy. Although these agents may also be used to induce puberty in boys and to treat androgen deficiency in hypogonadotropic hypogonadism, the major use of these preparations is in the initiation and maintenance of spermatogenesis in hypogonadotropic men who desire fertility.
Gonadotropin Therapy in Androgen Deficiency
It is known that hCG binds to Leydig cell LH receptors and stimulates the production of testosterone. Peripubertal boys with hypogonadotropic hypogonadism and delayed puberty can be treated with hCG instead of testosterone to induce pubertal development. The initial regimen of hCG is usually 1,000IU to 2,000IU administered intramuscularly two to three times a week72. The clinical response is monitored, and testosterone levels are measured about every two to three months. Dosage adjustments of hCG may be needed to determine an optimal schedule. Increasing doses of hCG may reduce testicular stimulation by down-regulating the end-organ; thus, a more optimal result may occur with less frequent or reduced dosing.The half-life of hCG is long. The advantages of hCG over testosterone in this setting include the stimulation of testicular growth, which may be an important issue for some men. Use of hCG may also yield greater stability of testosterone levels and fewer fluctuations in hypogonadal symptoms73. In addition, hCG treatment is necessary for stimulating enough intratesticular testosterone to allow the initiation of spermatogenesis. The disadvantages of hCG include the need for more frequent injections and the greater cost.
Gonadotropin Therapy for Induction of Spermatogenesis
Male patients with an onset of hypogonadotropic hypogonadism before completion of pubertal
14
Reference Section
three times a week for another six months. If pregnancy occurs, the patients regimen can be switched to only hCG to allow continued spermatogenesis for subsequent potential pregnancies. After delivery, if no further pregnancies are desired, the patient can be switched to testosterone therapy if desired, or long-term hCG therapy can be continued in conjunction with appropriate contraceptive measures, if needed. Rarely, antibodies against hCG may arise and prevent any response to therapy; in such a case, human LH may be effective79. Recombinant LH has recently become available and may be of use in selected patients.
GnRH Therapy
A s s i s t e d R e p r o d u c t i v e Te c h n o l o g y
The ability to perform in vitro fertilization with intracytoplasmic sperm injection directly into the egg has revolutionised the approach to male subfertility. A single sperm or immature form retrieved from the testicle is sufficient to fertilise an egg and provide a reasonable chance at pregnancy. In vitro fertilization with intracytoplasmic sperm injection may be a viable option in many men with hypogonadism who cannot otherwise be induced to produce enough sperm to result in pregnancy as well as in the presence of a female factor that may further make pregnancy by the couple difficult or impossible. The procedure is expensive and seldom covered by health insurance; therefore, this technology will generally not replace conventional gonadal stimulation protocols. Intrauterine insemination may also be a lowcost option in suitable women when the man has mild to moderate oligospermia.
P i t u i t a r y Tu m o r s
In patients with an otherwise intact pituitary gland and hypogonadotropic hypogonadism, synthetic GnRH can be given in a pulsatile fashion, subcutaneously through a pump every two hours. GnRH therapy is monitored by measuring LH FSH, and testosterone levels every two weeks until levels are in the normal range, at which point monitoring can be adjusted to every two months. GnRH can be used to initiate pubertal development, maintain virilization and sexual function and initiate and maintain spermatogenesis. In most patients, these effects may take from three to 15 months to achieve sperm production80. As with gonadotropin therapy, fertility can be achieved with very low sperm counts often in the range of one million/mL. GnRH may be more effective than gonadotropin stimulation in increasing testicular size and initiating spermatogenesis in many patients with hypogonadotropic hypogonadism81.
O t h e r Tr e a t m e n t C o n s i d e r a t i o n s
Antiestrogen Therapy in Oligospermia
Patients with acquired, hypogonadotropic hypogonadism may require assessment for a possible pituitary tumor with appropriate pituitary imaging studies such as MRI and determination of a prolactin level. Depending on the presence or absence of a tumor, other hormonal testing may be indicated, including thyroid and adrenal function tests. Further evaluation and treatment options would depend on what hormonal deficits are present, the size and site of the tumor, the operability of the tumor, and the patients preferences in specific circumstances. If a prolactinoma is present, therapy is directed toward correcting this problem before the initiation of other therapy. Medical therapy with bromocriptine, pergolide or cabergoline may effectively reduce prolactin levels sufficiently to allow gonadal function to resume or allow stimulation with gonadotropins. Even when prolactin levels cannot be normalized, hCG therapy alone or in conjunction with human menopausal gonadotropin (or FSH) therapy may stimulate spermatogenesis in treated prolactinomas and result in pregnancies84. Surgical therapy should especially be considered for significant pituitary tumors that are not prolactinsecreting microadenomas. Surgical treatment may also be an option in prolactin-secreting microadenomas if patients have severe side effects from medications, or prefer this approach after being appropriately informed of the risks and benefits of medical versus surgical management.
Long-term use of low-dose clomiphene citrate at 25mg daily to increase pituitary stimulation of testicular function has often been attempted in men with oligospermia82. Tamoxifen has been used in countries other than the US. The results are unpredictable and no long-term, prospective studies have demonstrated efficacy. Studies have generally shown no significant changes in semen variables or pregnancy rates83. Currently, we do not recommend the general use of clomiphene citrate or tamoxifen for the treatment of oligospermia in male patients.
15

Gynecomastia
particular, are important physical manifestations for differential diagnosis.

Laborator y and Ancillar y Evaluation
Many men have psychological problems resulting from gynecomastia. This problem should be taken seriously and discussed with the patient. Use of aromatase inhibitors such as testolactone has been tried, but has yielded limited benefit. A breast reduction surgical procedure is often required for psychological wellbeing.
Psychological Counseling
Laboratory testing is directed toward determining whether the patient has abnormalities of reproductive hormones and whether the abnormalities are indicative of testicular or hypothalamic-pituitary disease.The initial laboratory testing should include a morning blood sample for testosterone, prolactin, FSH and LH levels. A semen analysis is needed if fertility potential is an issue. If testosterone levels are low to normal and the symptoms and signs indicate hypogonadism, the testosterone study should be repeated and SHBG or a free testosterone level by equilibrium dialysis should be determined to help diagnose a hypogonadal state because total testosterone levels may be normal in the setting of hypogonadism if the SHBG levels are increased. To diagnose hypergonadotropic hypogonadism, FSH is especially important because FSH has a longer halflife, is more sensitive, and demonstrates less variability than LH. Pooled LH samples (three preferred) may help reduce problems with LH variability associated with a short half-life and pulsatile secretion. Dynamic testing of the hypothalamic-pituitarytesticular axis should be done by an endocrinologist and reserved for patients in whom the results of baseline diagnostic testing are equivocal, although interpretation of the results of dynamic testing may be poorly defined. In acquired hypogonadotropic hypogonadism, a prolactin level and pituitary imaging study should be undertaken to assess the patient for a possible hypothalamic-pituitary disorder, such as a pituitary tumor. Testing of the thyroid, adrenal, and growth hormone axes is also indicated. Chromosomal analysis should be considered in men with prepubertal-onset hypergonadotropic hypogonadism to evaluate for Klinefelters syndrome and related disorders. Bone densitometry should be taken in men with chronic, untreated hypogonadal disorders, to aid in decision making about treatment options to prevent and treat osteoporosis. Testicular ultrasonography should be done in patients with clinical findings suggestive of a scrotal or testicular mass.
Men with hypogonadotropic disorders frequently have associated mood disturbances, including depression, aggression, poor self-esteem, and learning problems. In such cases, psychological counseling is often needed to allow proper identification and treatment of these problems. Counseling should also include significant others, if possible.
Summary
The major objectives of the initial assessment of a patient with possible hypogonadism are to distinguish primary gonadal failure (hypergonadotropic hypogonadism with low testosterone and increased FSH and LH levels) from hypothalamic-pituitary disorders (hypogonadotropic hypogonadism with low testosterone and low to normal FSH and LH levels) and to make a specific diagnosis. The initial clinical manifestations may vary, depending on whether the onset of the disorder was prepubertal or postpubertal. Men with hypogonadotropic disorders may achieve fertility with gonadal stimulation. Men with hypergonadotropic disorders are treated with testosterone to achieve virilization and are usually, but not invariably, incapable of achieving fertility.
Histor y and Physical Examination
A history of major medical problems, medications, toxic exposures, fertility problems, and developmental milestones should especially be noted. Low libido, impotence, fatigue, impaired concentration, and sexual dysfunction are important presenting problems and need to be asked about specifically because most men will not seek medical attention for these symptoms alone. The degree of pubertal development, eunuchoid proportions, anosmia, hyposmia, gynecomastia, abnormal hair growth and distribution, abnormal genitalia, presence of varicocele, findings on prostate examination, and testicular size and consistency, in
16
Reference Section
In the evaluation of abnormal semen findings, testicular biopsy should be reserved for patients with normal results of hormonal studies and azoospermia to evaluate for obstruction or congenital absence of the vasa and possible surgical repair or use of in vitro fertilization with intracytoplasmic sperm injection.
D i a g n o s i s a n d Tr e a t m e n t
symptoms and signs of hypogonadism should be identified through appropriate questioning of the patient and a directed physical examination. Hormonal and ancillary testing should be performed in a costefficient and clinically appropriate manner to allow pertinent treatment considerations. Testosterone replacement therapy can often enable the patient to function in a more normal manner and decrease the risk of future problems with fertility, mood disturbances, fatigue, impaired virilization, and osteoporosis. Further studies are needed to determine the influence of testosterone replacement therapy on cardiovascular risk. Importantly, these guidelines demonstrate the need for meaningful, long-term studies of hypogonadal disorders in general and of aging men in particular. The ultimate goals are to improve both duration and quality of life and to allow people to reach their full potential, regardless of age.
An overall summary of clinical and laboratory findings, potential diagnoses, and recommended evaluation or treatment strategies in adult male patients with hypogonadism is presented in Table 1.
Conclusion
The recognition, evaluation, and treatment of hypogonadism in the male patient are often dismissed by the patient and overlooked by the physician. The
Table 1: Summary of Findings, Potential Diagnoses, and Recommended Strategies in Adult Male Patients With Hypogonadism Testicular size Not palpable Not palpable <5 mL FSH LH Testosterone N or Semen analysis Azoospermia Azoospermia Azoospermia, oligospermia Diagnosis Anorchism Bilateral cryptorchidism Kallmanns syndrome, hypogonadotropic hypogonadism for spermatogenesis Klinefelters syndrome, other hypergonadotropic syndromes Germinal damage: toxins, idiopathic Adult-acquired, hypogonadotropic hypogonadism Evaluation or treatment Surgical exploration Surgical exploration T for virilization; hCG _hMG (or FSH) or GnRH
<5mL
N or
Azoospermia
815mL 1020mL
Azoospermia oligospermia Oligospermia
1020mL 1520mL
N or N or N or (variable) (variable) l N or N N
Variable Senescence
Oligospermia Varicocele, drugs, idiopathic
Variable Phenotype (variable) (variable) 2030mL N N N
Variable
T-receptor defects, Reifensteins Syndrome Obstruction
Azoospermia
Karyotype to confirm;T for virilization Fertility: IVF with ICSI (?) Pituitary MRI; treat pituitary disorder with prolactin if present; otherwise treat as Kallmanns syndrome T if symptomatic with low T Fertility: varicocele repair if significant varicocele present. Optimize female factor; IVF with ICSI Variable (depending on degree): medical or surgical therapy Fertility: surgical repair; IUI, IVF with ICSI
FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; hCG = human chorionic gonadotropin; hMG = human menopausal gonadotropin; ICSI = intracytoplasmic sperm injection; IUI = intrauterine insemination; IVF = in vitro fertilization; LH = luteinizing hormone; MRI = magnetic resonance imaging; N = normal; SHBG = sex-hormone-binding globulin;T = testosterone. Normal testicular size is 2030mL.Testicular size is used here as a clinical finding to help narrow the differential diagnosis. Some variation beyond the listed ranges may exist for a specific condition. Use of this variable is optional; the diagnosis should be based on the total clinical picture. Because of changes in SHBG levels, total testosterone may be in the normal range in the setting of low testosterone production. Level of SHBG or free testosterone should be used in this setting to determine whether treatment options should be considered.

References
Endocrine Practice, vol. 8, no. 6 (November/December 2002), p. 439. Endocrine Practice, 8 (2002), pp. 439456. T L Stedman (1995), Stedmans Medical Dictionary, 26th ed., Baltimore:Williams & Wilkins, p. 836. Endocrine Practice, vol. 8, no. 6 (November/December 2002), p. 440. E D Nottelmann, E J Susman, L D Dorn, et al., Developmental Processes in Early Adolescence: Relations among Chronologic Age, Pubertal Stage, Height, Weight and Serum Levels of Gonadotropins, Sex Steroids and Adrenal Androgens, J. Adolesc. Healthcare, 8 (1987), pp. 246260. 6. AACE Hypogonadism Guidelines, Endocrine Practice, vol. 8, no. 6 (2002), p. 441. 7. D I Spratt, L S ODea, D Schoenfeld, J Butler, P N Rao, and W F Crowley Jr, Neuroendocrine-gonadal Axis in Men: Frequent Sampling of LH, FSH and Testosterone, Am. J. Physiol., 254 (5 part 1), pp. E658E666. 8. J F Dunn, B C Nisula, and D Rodbard, Transport of Steroid Hormones: Binding of 21 Endogenous Steroids to Both Testosterone-Binding Globulin and Corticosteroid-binding Globulin in Human Plasma, J. Clin. Endocrinol. Metab., 53 (1981), pp. 5868. 9. R J Santen, The Testes, in P Felig, J Baxter, and L Frohman (eds.), Endocrinology and Metabolism (1995), New York: McGraw- Hill, pp. 885972. 10. H R Nankin and J J Calkins, Decreased Bioavailable Testosterone in Aging Normal and Impotent Men, J. Clin. Endocrinol. Metab., 63 (1986), pp. 1,4181,420. 11. C Carani, D Zini, A Baldini, L Della Casa, A Ghizzani, and P Marrama,Effects of Androgen Treatment in Impotent Men with Normal and Low Levels of Free Testosterone, Arch. Sex. Behav., 19 (1990), pp. 223234. 12. H J Baskin, Endocrinologic Evaluation of Impotence, South Med. J., 82 (1989), pp. 446449. 13. K Demisch and T Nickelsen, Distribution of Testosterone in Plasma Proteins During Replacement Therapy with Testosterone Enanthate in Patients Suffering from Hypogonadism, Andrologia, 15 (1983), pp. 536541. 14. S M Harman, E J Metter, J D Tobin, J Pearson, and M R Blackman,Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men: Baltimore Longitudinal Study of Aging, J. Clin. Endocrinol. Metab., 86 (2001), pp. 724731. 15. AACE Hypogonadism Guidelines, Endocrine Practice, vol. 8, no. 6 (2002), p. 442. 16. R J Santen and C A Paulsen, Hypogonadotropic Eunuchoidism II: Gonadal Responsiveness to Exogenous Gonadotropins, J. Clin. Endocrinol. Metab., 36 (1973), pp. 5563. 17. R S Swerdloff and C Wang, Diagnosis of Infertility, Up-to-Date (2000). 18. R J Santen, J M Leonard, R J Sherins, H M Gandy, and C A Paulsen, Short- and Long-term Effects of Clomiphene Citrate on the Pituitary-testicular Axis, J. Clin. Endocrinol. Metab., 33 (1971), pp. 970979. 19. M G Forest,How Should We Perform the Human Chorionic Gonadotrophin (hCG) Stimulation Test?, Int. J.Androl., 6 (1983), p. 1. 20. M P Leonard, C J Nickel, and A Morales, Hyperprolactinemia and Impotence:Why,When and How to Investigate, J. Urol., 142 (1989), pp. 992994. 21. K D Smith and E Steinberger, What is Oligospermia?, in P Troen and HR Nankin (eds.), The Testis in Normal and Infertile Men (1977), New York: Raven Press, p. 489. 22. AACE Hypogonadism Guidelines, Endocr. Pract., vol. 8, no. 6 (2002), p. 443. 23. S Plymate, Hypogonadism, Endocrinol. Metab. Clin. North. Am., 23 (1994), pp. 749772. 24. S R Plymate and C A Paulsen, Klinefelters Syndrome, in R King and A Motulsky (eds.), The Genetic Basis of Common Disease (1989), New York: Oxford University Press, pp. 876894. 25. C J Bagatell and W J Bremner, Androgens in Men-uses and Abuses, N. Engl. J. Med., 334 (1996), pp. 707714. 26. AACE Hypogonadism Guidelines, Endocr. Pract., vol. 8, no. 6 (2002), p. 444. 27. C Marchini, R Lonigro, L Verriello, L Pellizzari, P Bergonzi, and G Damante,Correlations Between Individual Clinical Manifestations and CTG Repeat Amplification in Myotonic Dystrophy, Clin. Genet., 57 (2000), pp. 7482. 28. P Saenger and E O Reiter, Management of Cryptorchidism, Trends. Endocrinol. Metab., 3 (1992), p. 249. 29. L J Siemons and C H Mahler,Hypogonadotropic Hypogonadism in Hemochromatosis: Recovery of Reproductive Function after Iron Depletion, J Clin Endocrinol Metab., 65 (1987), pp. 585587. 30. J P Hardelin and C Petit, A Molecular Approach to the Pathophysiology of the X Chromosome-linked Kallmanns Syndrome, Baillieres Clin. Endocrinol. Metab., 9 (1995), pp. 489507. 31. R J Santen and C A Paulsen,Hypogonadotropic Eunuchoidism: I Clinical Study of the Mode of Inheritance, J. Clin. Endocrinol. Metab., 36 (1973), pp. 4754. 32. P D Woolf, R W Hamill, J V McDonald, L A Lee, and M Kelly, Transient Hypogonadotropic Hypogonadism Caused by Critical Illness, J. Clin. Endocrinol. Metab., 60 (1985), pp. 444450. 33. A S Dobs, M A Dempsey, P W Ladenson, and B F Polk, Endocrine Disorders in Men Infected with Human
1. 2. 3. 4. 5.
18
Reference Section
19
Immunodeficiency Virus, Am. J. Med., 84 (3 pt. 2) (1988), pp. 611616. 34. J S Tenover, Androgen Administration to Aging Men, Endocrinol. Metab. Clin. North. Am., 23 (1994), pp. 877892. 35. C M Swartz and M A Young,Low Serum Testosterone and Myocardial Infarction in Geriatric Male Inpatients, J. Am. Geriatr. Soc., 35 (1987), pp. 3944. 36. D Simon, P Preziosi, E Barrett-Connor, et al., The Influence of Aging on Plasma Sex Hormones in Men:The Telecom Study, Am. J. Epidemiol., 135 (1992), pp. 7891. 37. A Vermeulen, Androgens and Male Senescence, in E Nieschlag and H M Behre (eds.), Testosterone: Action, Deficiency, Substitution (1990), Berlin: Springer-Verlag. 38. J D Veldhuis, R J Urban, G Lizarralde, M L Johnson, and A Iranmanesh,Attenuation of Luteinizing Hormone Secretory Burst Amplitude as a Proximate Basis for the Hypoandrogenism of Healthy Aging in Men, J. Clin. Endocrinol. Metab., 75 (1992), pp. 707713. 39. J S Tenover, Effects of Testosterone Supplementation in the Aging Male, J. Clin. Endocrinol. Metab., 75 (1992), pp. 1,0921,098. 40. A Vermeulen, Androgen Replacement Therapy in the Aging Male A Critical Evaluation, J. Clin. Endocrinol. Metab., 86 (2001), pp. 2,3802,390. 41.W Hubert, Psychotropic Effects of Testosterone, in E Nieschlag and H M Behre (eds.), Testosterone: Action, Deficiency, Substitution (1990), Berlin: Springer-Verlag. 42. A S Burris, S M Banks, C S Carter, J M Davidson, and R J Sherins,A Long-term, Prospective Study of the Physiologic and Behavioral Effects of Hormone Replacement in Untreated Hypogonadal Men, J.Androl., 13 (1992), pp. 297304. 43. American Association of Clinical Endocrinologists,AACE Clinical Practice Guidelines for the Evaluation and Treatment of Male Sexual Dysfunction, Endocr. Pract., 4 (1998), pp. 219235. 44. A A Abbasi, D Rudman, C R Wilson, et al.,Observations on Nursing Home Residents with a History of Hip Fracture, Am. J. Med. Sci., 310 (1995), pp. 229234. 45. O Arisaka, M Arisaka, Y Nakayama, S Fujiwara, and K Yabuta, Effect of Testosterone on Bone Density and Bone Metabolism in Adolescent Male Hypogonadism, Metabolism, 44 (1995), pp. 419423. 46. A C Scane,A M Sutcliffe, and R M Francis,Osteoporosis in Men, Baillieres Clin. Rheumatol., 7 (1993), pp. 589-601. 47. JJ van der Werff ten Bosch and A Bot, Some Skeletal Dimensions of Males with Isolated Gonadotrophin Deficiency, Neth. J. Med., 41 (1992), pp. 259263. 48. T Rosen, S Eden, G Larson, L Wilhelmsen, and B A Bengtsson, Cardiovascular Risk Factors in Adult Patients with Growth Hormone Deficiency, Acta. Endocrinol. (Copenh.), 129 (1993), pp. 195200. 49. A J Weissberger and K K Ho,Activation of the Somatotropic Axis by Testosterone in Adult Males: Evidence for the Role of Aromatization, J. Clin. Endocrinol. Metab., 76 (1993), pp. 1,4071,412. 50. C J Bagatell and W J Bremner, Androgen and Progestagen Effects on Plasma Lipids, Prog. Cardiovasc. Dis., 38 (1995), pp. 255271. 51. K E Friedl, C J Hannan Jr, R E Jones, and S R Plymate, High-density Lipoprotein Cholesterol is Not Decreased if an Aromatizable Androgen is Administered, Metabolism, 39 (1990), pp. 6974. 52. D S Oppenheim, S L Greenspan, N T Zervas, D A Shoenfeld, and A Klibanski,Elevated Serum Lipids in Hypogonadal Men with and without Hyperprolactinemia, Ann. Intern. Med., 111 (1989), pp. 288292. 53. E L Barrett-Connor, Testosterone and Risk Factors for Cardiovascular Disease in Men, Diabete. Metab., 21 (1995), pp. 156161. 54. L Berglund, K Carlstrom, R Stege, et al., Hormonal Regulation of Serum Lipoprotein (a) Levels: Effects of Parenteral Administration of Estrogen or Testosterone in Males, J. Clin. Endocrinol. Metab., 81 (1996), pp. 2,6332,637. 55. A A Ajayi, R Mathur, and P V Halushka, Testosterone Increases Human Platelet Thromboxane A2 Receptor Density and Aggregation Responses, Circulation, 91 (1995), pp. 2,7422,747. 56. P J Snyder, Clinical Use of Androgens, Annu. Rev. Med., 35 (1984), pp. 207217. 57. H R Nankin, Hormone Kinetics after Intramuscular Testosterone Cypionate, Fertil. Steril., 47 (1987), pp. 1,0041,009. 58. R Z Sokol,A Palacios, L A Campfield, C Saul, and R S Swerdloff,Comparison of the Kinetics of Injectable Testosterone in Eugonadal and Hypogonadal Men, Fertil. Steril., 37 (1982), pp. 425430. 59. A M Matsumoto, Clinical Use and Abuse of Androgens and Antiandrogens, in KL Becker (ed.), Principles and Practice of Endocrinology and Metabolism (1990), Philadelphia: JB Lippincott, p. 991. 60. A W Meikle, N A Mazer, J F Moellmer, et al., Enhanced Transdermal Delivery of Testosterone across Non-scrotal Skin Produces Physiological Concentrations of Testosterone and its Metabolites in Hypogonadal Men, J. Clin. Endocrinol. Metab., 74 (1992), pp. 623628. 61. J C Findlay,V Place, and P J Snyder, Treatment of Primary Hypogonadism in Men by the Transdermal Administration of Testosterone, J Clin Endocrinol Metab., 68 (1989), pp. 369373.

62. G R Cunningham, E Cordero, and J I Thornby, Testosterone Replacement with Transdermal Therapeutic Systems: Physiological Serum Testosterone and Elevated Dihydrotestosterone Levels, JAMA, 261 (1989), pp. 2,5252,530. 63.C Wang, N Berman, JA Longstreth, et al., Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site versus Four Sites; A General Clinical Research Center Study, J Clin Endocrinol Metab., 85 (2000), pp. 964969. 64. C Wang, R S Swerdloff, A Iranmanesh, et al. (Testosterone Gel Study Group), Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength and Body Composition Parameters in Hypogonadal Men, J. Clin. Endocrinol. Metab., 85 (2000), pp. 2,8392,853. 65. R S Swerdloff, C Wang, G Cunningham, et al., Long-term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men, J. Clin. Endocrinol. Metab., 85 (2000), pp. 4,5004,510. 66. C Wang, R S Swerdloff, A Iranmanesh, et al., Effects of Transdermal Testosterone Gel on Bone Turnover Markers and Bone Mineral Density in Hypogonadal Men, Clin. Endocrinol. (Oxf.), 54 (2001), pp. 739750. 67.T H Douglas, R R Connelly, D G McLeod, S J Erickson, R Barren III, and G P Murphy, Effect of Exogenous Testosterone Replacement on Prostate-specific Antigen and Prostate-specific Membrane Antigen Levels in Hypogonadal Men, J. Surg. Oncol., 59 (1995), pp. 246250. 68. H M Behre, J Bohmeyer, and E Nieschlag, Prostate Volume in Testosterone-treated and -untreated Hypogonadal Men in Comparison to Age-matched Normal Controls, Clin. Endocrinol. (Oxf.), 40 (1994), pp. 341349. 69. C W Bardin, R S Swerdloff, and R J Santen,Androgens: Risks and Benefits, J. Clin. Endocrinol. Metab., 73 (1991), pp. 47. 70. A Palacios, L A Campfield, R D McClure, B Steiner, and R S Swerdloff, Effect of Testosterone Enanthate on Hematopoiesis in Normal Men, Fertil. Steril., 40 (1983), pp. 100104. 71. R E Sandblom, A M Matsumoto, R B Schoene, et al., Obstructive Sleep Apnea Syndrome Induced by Testosterone Administration, N. Engl. J. Med., 308 (1983), pp. 508510. 72. R B Christensen, A M Matsumoto, and W J Bremner, Idiopathic Hypogonadotropic Hypogonadism with Anosmia (Kallmanns Syndrome), Endocrinologist, 2 (1992), p. 332. 73. L Gooren, Hypogonadotropic Hypogonadal Men Respond Less Well to Androgen Substitution Treatment than Hypergonadotropic Hypogonadal Men, Arch. Sex. Behav., 17 (1988), pp. 265270. 74. A M Matsumoto,Hormonal Therapy of Male Hypogonadism, Endocrinol. Metab. Clin. North Am., 23 (1994), pp. 857875. 75. A Lenzi, F Lombardo, L Gandini, P Alfano, and F Dondero,Computer-assisted Sperm Motility Analysis at the Moment of Induced Pregnancy During Gonadotropin Treatment for Hypogonadotropic Hypogonadism, J. Endocrinol. Invest., 16 (1993), pp. 683686. 76. A S Burris, H W Rodbard, S J Winters, and R J Sherins,Gonadotropin Therapy in Men with Isolated Hypogonadotropic Hypogonadism: The Response to Human Chorionic Gonadotropin is Predicted by Initial Testicular Size, J. Clin. Endocrinol. Metab., 66 (1988), pp. 1,1441,151. 77. E Vicari,A Mongioi,A E Calogero, et al.,Therapy with Human Chorionic Gonadotrophin Alone Induces Spermatogenesis in Men with Isolated Hypogonadotrophic Hypogonadism Long-term Follow-up, Int. J.Androl., 15 (1992), pp. 320329. 78. G Schaison, J Young, M Pholsena, K Nahoul, and B Couzinet, Failure of Combined Follicle-stimulating Hormonetestosterone Administration to Initiate and/or Maintain Spermatogenesis in Men with Hypogonadotropic Hypogonadism, in J. Clin. Endocrinol. Metab., 78 (1994), p. 846; J. Clin. Endocrinol. Metab., 77 (1993), pp. 1,5451,549. 79. R B Thau, M Goldstein,Y Yamamoto, G N Burrow, D Phillips, and C W Bardin, Failure of Gonadotropin Therapy Secondary to Chorionic Gonadotropin-induced Antibodies, J. Clin. Endocrinol. Metab., 66 (1988), pp. 862867. 80. W Aulitzky, J Frick, and G Galvan, Pulsatile Luteinizing Hormone-releasing Hormone Treatment of Male Hypogonadotropic Hypogonadism, Fertil. Steril., 50 (1988), pp. 480486. 81. J Schopohl, Pulsatile Gonadotrophin Releasing Hormone versus Gonadotrophin Treatment of Hypothalamic Hypogonadism in Males, Hum Reprod., 8 (1993), suppl. 2, pp. 175179. 82. P J Sorbie and R Perez-Marrero,The Use of Clomiphene Citrate in Male Infertility, J. Urol., 131 (1984), pp. 425429. 83. R Breznik and E Borko, Effectiveness of Antiestrogens in Infertile Men, Arch. Androl., 31 (1993), pp. 4348. 84. K Isurugi,T Kajiwara,Y Hosaka, and S Minowada,Successful Gonadotrophin Treatment of Hypogonadism in Postoperative Patients with Macroprolactinoma and Persistent Hyperprolactinaemia, Int. J. Androl., 16 (1993), pp. 306310.
20

AACE Guidelines

Uploaded by

Copyright:

Available Formats

AACE Guidelines

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

AACE Guidelines

Uploaded by

Copyright:

Available Formats

What are the target populations discussed for these clinical practice guidelines?

What are the target populations discussed for these clinical practice guidelines?

What are the initial hormonal evaluations generally consist of?

What are the initial hormonal evaluations generally consist of?

Reference Section

The American Association of Clinical Endocrinologists H y p o g o n a d i s m Ta s k Fo rc e

AACE Hypogonadism Guidelines Update

AACE Hypogonadism Guidelines Update

AACE Hypogonadism Guidelines Update

AACE Hypogonadism Guidelines Update

See earlier discussion of hemochromatosis in Hypergonadotropic Hypogonadism section.

AACE Hypogonadism Guidelines Update

See subsequent sections relating to therapy for hypogonadotropic hypogonadism.

AACE Hypogonadism Guidelines Update

AACE Hypogonadism Guidelines Update

Male patients with an onset of hypogonadotropic hypogonadism before completion of pubertal

AACE Hypogonadism Guidelines Update

particular, are important physical manifestations for differential diagnosis.

Azoospermia oligospermia Oligospermia

Oligospermia Varicocele, drugs, idiopathic

Variable Phenotype (variable) (variable) 2030mL N N N

T-receptor defects, Reifensteins Syndrome Obstruction

AACE Hypogonadism Guidelines Update

AACE Hypogonadism Guidelines Update

You might also like